VERITAS Vision System Is Introduced by Johnson & Johnson

Johnson & Johnson Vision,* a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, today announced the global availability of the VERITAS Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort.

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting.

Approximately 50% of people over the age of 75 have cataracts1 and cataract surgery is one of the most common outpatient procedures performed today with a success rate of approximately 98%.2 Phacoemulsification is the most common cataract surgery technique3 and allows surgeons to effectively emulsify and efficiently remove the eye’s internal lens when it has become cloudy from cataracts. It is a delicate procedure that requires significant effort and control, which can be taxing on the surgeon. Equipment that surgeons can rely on through surgery is critical to optimizing the circumstances for surgical success.

“In my experience, the advancements in fluidics management and usability of the VERITAS Vision System have made a marked improvement in safety and stability of the phaco procedure,” said Jason Jones, M.D.§, Jones Eye Clinic, Sioux City, Iowa. “I’ve found I can glide through any lens density with less surge, and the level of chamber stability I’ve experienced with VERITAS gives me more confidence to take advantage of Venturi mode, the more powerful phaco setting.”

“Surgeon-centered equipment design is vital for an exacting and taxing procedure like phacoemulsification,” said Dr. Marco Tavolato, Head of Eye Centre, Chioggia Hospital, Italy.** “The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons’ needs. From safety features like Hybrid Fluidics Technology, to the nuances of a more ergonomic design for comfort and control, these advancements have made a measurable difference in my surgical day, and ease even the most challenging phaco cases.”

The VERITAS Vision System features several innovations to provide a better surgical experience, including:

  • Less surge, more stability
    • Hybrid Fluidics Technology minimizes post-occlusion surge to protect intraocular structures and provide exceptional chamber stability.††,‡‡
    • Intelligent Occlusion Sensing Technologies automatically respond to occlusions to preserve a calm, stable chamber even in dense cataract cases.§§
  • Exceptional phacoemulsification efficiency
    • Built using the company’s leading WHITESTAR technology combined with elliptical tip movement for ultra-smooth cutting, even in dense or advanced cataracts, providing an efficient lens extraction that uses less energy.***
    • Dual Pump System allows access to both Peristaltic and Venturi pumps with on-demand transition between the two at every step, allowing surgeons to adapt to clinical needs.‡‡
  • Surgeon-centered ergonomics for maneuverability and comfort
    • Between 52-80% of ophthalmologists report back and neck pain because of their work4 and 43% take breaks during surgery due to pain.5
    • An ergonomically designed foot pedal provides total control and a more comfortable experience.†††

“On top of providing a safe and stable procedure for cataract patients, we wanted to also offer a more efficient and comfortable phacoemulsification experience for surgeons, especially knowing most will perform multiple cataract surgeries every day,” said Warren Foust, Worldwide President, Surgical at Johnson & Johnson Vision.‡‡‡ “Our VERITAS Vision System delivers high-performing, reliable tools for a smooth, effective cataract surgery for patients while also prioritizing surgeon well-being.”

The VERITAS Vision System is the latest addition to the company’s full suite of industry leading products for the treatment of cataracts. The global launch comes as the Johnson & Johnson Vision celebrates two 20-year anniversaries: WHITESTAR micropulse technology, a major advancement in phacoemulsification efficiency10, the TECNIS Family of IOLs, which established the company’s legacy of innovation in cataract treatment.

The VERITAS Vision System is now available for ophthalmologists across the United States, Europe and select markets in the Asia Pacific region to use in their treatment of cataracts and will be available later this year in Chile and Brazil.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”